摘要
目的探讨依达拉奉联合灯盏花素注射液治疗急性缺血性脑血管病的临床研究及对内皮素-1(ET-1)、胰岛素抵抗与神经功能的影响。方法选择2016年2月—2017年2月我院就诊的急性缺血性脑血管病病人104例,采用抽签法分为观察组和对照组,各52例。在常规治疗基础上,对照组使用依达拉奉注射液治疗,观察组使用依达拉奉联合灯盏花素注射液治疗,均连续治疗14 d。比较两组治疗前后血液流变学、血浆ET-1、胰岛素抵抗指数(HOMA-IR)及美国国立卫生研究院卒中量表(NIHSS)评分的变化,并比较临床疗效。结果治疗后,两组全血黏度、血浆黏度、纤维蛋白原、血细胞比容较治疗前均显著降低(P<0.05);观察组全血黏度、血浆黏度、纤维蛋白原、血细胞比容均明显低于对照组(P<0.01);治疗后两组血浆ET-1、HOMA-IR较治疗前均显著降低(P<0.05),观察组血浆ET-1、HOMA-IR均明显低于对照组(P<0.01);治疗后两组NIHSS评分较治疗前均显著降低(P<0.05),观察组NIHSS评分明显低于对照组(P<0.01)。观察组临床疗效总有效率明显高于对照组(P<0.05)。结论急性缺血性脑血管病病人应用依达拉奉联合灯盏花素注射液效果显著,可有效改善病人神经功能,其内在机制可能与改善血浆ET-1表达及胰岛素抵抗有关。
Objective To study the curative efficacy of edaravone and breviscapine injection in the treatment of acute ischemic cerebrovascular disease（ICVD）and its effects on endothelin-1（ET-1）,insulin resistance,and neurological function.Methods One hundred and four patients with acute ICVD in our hospital from February 2016 to February 2017 were selected and divided into two groups according to lottery method：control group（n =52）treated with edaravone and observation group（n =52）treated with edaravone and breviscapine injection in the basis of routine treatment for 14 days.The changes of hemorheology,plasma ET-1,homeostasis model assessment of insulin resistance（HOMA-IR）,and the National Institutes of Health Stroke Scale（NIHSS）scores were compared between two groups before and after treatment,and the clinical efficacy was observed.Results After treatment,the whole blood viscosity,plasma viscosity,fibrinogen,and hematocrit in two groups were significantly lower than those before treatment（P 〈0.05）,which were significantly lower in observation group than those in control group（P 〈0.01）.After treatment,the plasma ET-1 and HOMA-IR in the two groups were significantly lower than those before treatment（P 〈0.01）,which were significantly lower in observation group than those in control group（P 〈0.05）.After treatment,the NIHSS scores in two groups were significantly lower than those before treatment（P〈 0.05）,which were significantly lower in observation group than those in control group（P 〈0.01）.The total effective rate was significantly higher in observation group than that in the control group（P 〈0.05）.Conclusion Edaravone and breviscapine injection can effectively improve the neurological function in patients with acute ICVD,and its mechanism may be related to the improvement of plasma ET-1 expression and insulin resistance.
作者
许春立
徐敉
顾育明
Xu Chunli;Xu Mi;Gu Yuming(Seventh People＇s Hospital,Shanghai University of Traditional Chinese Medicine,Shanghai 200137,China)
出处
《中西医结合心脑血管病杂志》
2018年第11期1490-1493,共4页
Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease
